Except for the PD-1 inhibitors, immunotherapy has been a virtual flop. See what happened to Rintega a few months ago. Provenge, anyone?
Both NKTR-102 and 105 were super superior curing cancer in mice. There may still be some poster presentations on the NKTR website.
Some math... 8K scripts times $150 wholesale is $1.2M per week, or about $60M per year. Need to kick it up an order of magnitude.
Not only is SNFCA deep in home construction loans, they are doubling down on mortgage servicing rights. In the MSR biz, you get to keep a portion of the monthly mortgage payment. Banks sell them off to companies like OCN and PHH. The idea is that you pay money up front to buy MSR's and get it back over time doing the collection. Problem is that in a falling rate environment people refinance and the MSR ends at that point. It's a losing business right now.
Another interesting NCE in the pipeline is TRVN oliceridine (TRV-130). It's first application is for specialized surgical/hospital use.
In a certain sense, KMPH missed the point of what is really needed for abuse deterrence. Apadaz and Norco have essentially equivalent likability taken as directed. Apadaz was superior in the methods that KMPH used to try to improve likability. But this methodology is being overtaken by events with the current heroin/fentanyl/etc. epidemic. What's happening is that people are becoming addicted to prescribed opioids. There is decent deterrence in current opioids and they cost a lot of money. So instead of manipulating the drugs they are on, addicts are switching to cheaper, more powerful street drugs. Apadaz does not, and has never made a claim to reduce or eliminate initial addiction potential.
The real objective is for effective pain relief without the addiction. NKTR-181 is a new chemical entity opioid, a molecule that is used whole and not broken down. At low/moderate dosage, it has shown ability to reduce pain to some extent without inducing euphoria and addiction. Emphasis on "some extent". NKTR has a long way to go to show it safely provides effective pain relief , but they are on the right road.
Don't underestimate the creativity of the drug world. There is now a "one jug" method of making methamphetamine. If the human body can break it down, chemists will find a way.
Aren't Movantik royalties ex-US now about mid single digits? I thought that's what the $26M cash payment was about.
Yes, likability study needs to be completely redone. 400 mg of NKTR-181 dose Phase 2 was too low, needs to be increased. Safety at higher dose also needs to be evaluated.
Which will occur first?
1. Clinical hold lifted on Phase 3 trial.
2. NWBO successfully resolves illegal stock distribution scheme with NASDAQ.
3. NWBO begins a clinical trial with one of the three companies it is negotiating with.
My prediction... All will occur on the 12th of Never.
I confused the two drugs. Thanks cow and james for correcting me. I'm wondering if I should delete that mistaken post.
30 minutes to infuse Keytruda outpatient, and up to 14 infusions (one every eight hours) for NKTR-214 in an ICU setting. That's at least five days in the hospital per dosing. Taking Keytruda is a spit in the bucket compared to NKTR-214 treatment.
It's probably safe to say that the AE's from this combo treatment are going to be greater than that from Keytruda alone.
Given the quality of life hits, the efficacy improvement has to be more than marginal for NKTR-214 to be a success in the marketplace.
You do have tier 1 coverage. The non-subsidized price is close to $300 for a thirty day supply.
Next level question is that at tier 1 $1000/year, will people take it daily, or will it be used only as needed? The Phase 1/2 results show that it is generally effective within a day, at the cost of discomfort in many patients.